Entecavir Anhydrous

Summary

Entecavir Anhydrous (CHEMBL713) is an approved small-molecule EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 190
• Chemistry: 277.28 Da · C12H15N5O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL713
Name	Entecavir Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	135398508
ChEBI	CHEBI:473990
Molecular formula	C12H15N5O3
Molecular weight	277.28
InChIKey	QDGZDCVAUDNJFG-FXQIFTODSA-N

SMILES: C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N

IUPAC name: 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one

ChEBI definition: Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2’-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme’s activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.

Pharmacological roles (ChEBI): EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor, antiviral drug.

Also known as: Anhydrous entecavir, entecavir, Entecavir

Parent form; salt/anhydrous children: CHEMBL5314362

Patent coverage: 5,648 distinct patent families (20,030 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 17,876 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 190.

Phase distribution

Phase	Trials
PHASE4	66
PHASE2	36
Not specified	33
PHASE3	29
PHASE1	15
PHASE1/PHASE2	7
PHASE2/PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03933384	PHASE4	RECRUITING	Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
NCT04032860	PHASE4	ACTIVE_NOT_RECRUITING	RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
NCT07189377	PHASE4	RECRUITING	Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
NCT07345611	PHASE4	NOT_YET_RECRUITING	Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B
NCT07345624	PHASE4	NOT_YET_RECRUITING	Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B
NCT00371150	PHASE4	COMPLETED	Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
NCT00393484	PHASE4	COMPLETED	A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection
NCT00597259	PHASE4	UNKNOWN	Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B
NCT00614471	PHASE4	COMPLETED	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
NCT00625339	PHASE4	COMPLETED	Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA
NCT00625560	PHASE4	COMPLETED	Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA
NCT00637663	PHASE4	COMPLETED	Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
NCT00663182	PHASE4	UNKNOWN	Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
NCT00718887	PHASE4	COMPLETED	Suboptimal Responders to Adefovir Switching to Entecavir
NCT00823550	PHASE4	UNKNOWN	Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
NCT00877760	PHASE4	COMPLETED	Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B
NCT00917761	PHASE4	UNKNOWN	Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B
NCT00921180	PHASE4	UNKNOWN	Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B
NCT00922207	PHASE4	COMPLETED	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
NCT00926757	PHASE4	COMPLETED	Prophylactic Use of Entecavir for Non-Hodgkin’s Lymphoma Patients With Resolved Hepatitis B
NCT00940485	PHASE4	COMPLETED	A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
NCT00986778	PHASE4	WITHDRAWN	Entecavir Plus Adefovir in Lamivudine-Resistant Patients
NCT01023217	PHASE4	COMPLETED	Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
NCT01148576	PHASE4	UNKNOWN	Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients
NCT01179594	PHASE4	WITHDRAWN	A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
NCT01266005	PHASE4	TERMINATED	A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients
NCT01341743	PHASE4	UNKNOWN	Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
NCT01354652	PHASE4	TERMINATED	Lactic Acidosis During Entecavir(ETV)Treatment
NCT01456312	PHASE4	UNKNOWN	HBsAg Related Response Guided Therapy
NCT01588912	PHASE4	UNKNOWN	Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir
NCT01594905	PHASE4	UNKNOWN	Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection
NCT01627223	PHASE4	TERMINATED	Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation
NCT01639066	PHASE4	COMPLETED	Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B
NCT01639092	PHASE4	COMPLETED	Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B
NCT01711567	PHASE4	COMPLETED	Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir
NCT01724723	PHASE4	UNKNOWN	Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment
NCT01765231	PHASE4	UNKNOWN	Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
NCT01768195	PHASE4	UNKNOWN	Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
NCT01829685	PHASE4	UNKNOWN	Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
NCT01833611	PHASE4	UNKNOWN	Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).